Genus（GENS.F）株式概要ジーナス社は北米、中南米、英国、その他のヨーロッパ、中東、ロシア、アフリカ、アジアで動物遺伝学会社として事業を展開している。 詳細GENS.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性5/6配当金4/6報酬今年は黒字化を達成 アナリストらは、株価が30.2%上昇するだろうとほぼ一致している。 リスク分析株式の流動性は非常に低い 今後3年間の収益は年平均2.7%減少すると予測されている。 財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見るGENS.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$31.0722.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7m785m2016201920222025202620282031Revenue UK£784.8mEarnings UK£55.5mAdvancedSet Fair ValueView all narrativesGenus plc 競合他社VericelSymbol: NasdaqGM:VCELMarket cap: US$1.7bAurinia PharmaceuticalsSymbol: NasdaqGM:AUPHMarket cap: US$2.0bVeracyteSymbol: NasdaqGM:VCYTMarket cap: US$3.1bSarepta TherapeuticsSymbol: NasdaqGS:SRPTMarket cap: US$1.9b価格と性能株価の高値、安値、推移の概要Genus過去の株価現在の株価UK£31.0752週高値UK£37.2552週安値UK£26.01ベータ0.901ヶ月の変化-6.30%3ヶ月変化n/a1年変化14.63%3年間の変化n/a5年間の変化-52.93%IPOからの変化103.31%最新ニュースお知らせ • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026お知らせ • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.お知らせ • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdom最新情報をもっと見るRecent updatesお知らせ • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026お知らせ • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.お知らせ • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdomお知らせ • Sep 04Genus plc Proposes Final Dividend for the Year 2025, Payable on December 5, 2025Genus plc proposed a final dividend of 21.7 pence per share for 2025. This is subject to shareholders' approval at the AGM and we have therefore not included it as a liability in these Financial Statements. The total proposed and paid dividend for year ended 30 June 2025 is 32.0 pence per share (2024: 32.0 pence per share). It is proposed that the final dividend will be paid on 5 December 2025 to the shareholders on the register at the close of business on 7 November 2025.お知らせ • May 02Genus plc Announces the Update in Relation to Its Innovative Prrs 1 Resistant Pig ProgrammeGenus announced that the U.S. Food and Drug Administration ("FDA") has approved the PRP gene edit for use in the U.S. food supply chain, in line with expectations. This landmark approval follows years of close collaboration with the FDA and is a significant step on the pathway to PRP commercialisation in the U.S. Genus believes successful U.S. commercialisation also requires approvals in key U.S. export markets, being Mexico, Canada and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China. Brazil, Colombia and, more recently, the Dominican Republic have already issued positive determinations for PRP, meaning those countries will regulate the PRP the same as any other pigs. PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. Recent research indicates that PRRS also increases the need for antibiotics by more than 200%.お知らせ • Mar 13+ 1 more updateGenus plc Appoints Andy Russell as Chief Financial Officer, Effective August 1, 2025The Board of Genus plc announced that it has appointed Andy Russell as Chief Financial Officer. Andy will commence with Genus and join the Board on 1 August 2025, taking over from Alison Henriksen after she retires from the Company on 31 July 2025, after more than five years in the role. Andy is an experienced CFO, who will join Genus after nearly 12 years with global medical device manufacturer Smith & Nephew plc. He currently serves as Senior Vice President, Group Finance and M&A, operating as deputy to the Group CFO and leading approximately 400 people globally as he oversaw Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This follows a succession of increasingly senior roles within the organisation, including CFO for the Global Orthopedics division, Interim President for EMEA and CFO for EMEA (while also acting as Finance lead for Global M&A and Strategic Projects). Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last three of them as a Director, Transaction Services in the National Markets Division and the Private Equity Group.お知らせ • Feb 26Genus plc Announces Retirement of Jason Chin as Non-Executive Director from the Board, Effective from the End of May 2025Genus plc announced that Professor Jason Chinhas informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board. The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded.お知らせ • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025お知らせ • Nov 21Genus plc Declares A Final DividendGenus plc declared a final dividend of 21.7 pence per Ordinary Share, at its AGM held on 20 November 2024.お知らせ • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Oct 22Genus plc Announces Retirement of Alison Henriksen as Chief Financial Officer, Until 31 July 2025Genus announced that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.お知らせ • Sep 05Genus plc Proposes Final Dividend for the Year Ended June 30, 2024, Payable on 6 December 2024Genus plc board proposed a final dividend of 21.7 pence per ordinary share, consistent with the prior year final dividend. Payable on, 6 December 2024 to the shareholders on the register at the close of business on 8 November 2024.お知らせ • Feb 16Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024Genus plc provided earnings guidance for the first half of fiscal 2024. For the first half period, management expects to report revenue of £334 Million.お知らせ • Dec 12Genus Appoints Ralph Heuser as Non-Executive Director, with effect from 1 January 2024Genus announced the appointment of Dr Ralph Heuser to the Board as a Non-Executive Director, with effect from 1 January 2024. Dr Heuser has had extensive experience in animal healthcare businesses globally, having worked at Pfizer, Boehringer Ingelheim, where he launched a PRRS vaccine in Germany, Novartis's Consumer and Animal Health divisions and more recentlyin global leadership roles at Elanco Animal Health, including as Vice President for Asia Pacific, Europe and International Commercial Operations. Dr Heuserhas a PhD in Agricultural Economics from the University of Bonn, Germany andis currently a Senior Advisor with Stonehaven Consulting (SC Group) AG. Dr Heuser brings widespread global experience in operations, commercial excellence, integration and the animal health industry generally, and his appointment follows an extensive search process using an external search agency.お知らせ • Nov 24+ 2 more updatesGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024お知らせ • Nov 23Genus plc Approves to Declare Final DividendGenus plc at its AGM held on 22 November 2023, approved to declare a final dividend of 21.7 pence per Ordinary Share.お知らせ • Oct 08Colombian Government Gives Positive Determination for Genus's PRRS Virus-Resistant PigsGenus plc announced that the government of Colombia has given a favourable regulatory determination for Genus's Porcine Reproductive and Respiratory Syndrome virus ("PRRS") resistant pigs. This enables the future sale of such pigs in Colombia. PRRS is one of the most significant diseases in the pig industry, causing severe respiratory distress, increased secondary infections, pregnancy loss and increased morbidity and mortality. There are currently no effective vaccines or treatments. The creation of a PRRS resistant pig therefore represents a significant step forward in the welfare of pigs by protecting themthem from this devastating virus. It is estimated that PRRS costs the US and EU pig industry approximately $2 billion each year. Genus has used its gene editing platform to develop pigs resistant to PRRS, by deleting a very small portion of the pigs' DNA that encodes a protein that the virus uses to enter and infect the pigs' cells. With this small gene edit, the pig is resistant to PRRS, as the virus is unable to enter the cells and replicate. The Colombian government is the first to issue a determination for Genus's PRRS resistant pigs, enabling the future commercialisation of the pigs. The PRRS resistant pigs will be treated in the same way as any other pigs in Colombia. Further regulatory approvals for the PRRS resistant pig are also being sought in the United States, Canada, China, Japan, Mexico, Brazil and other countries. Genus anticipates a decision from the United States Food and Drug Administration in the first half of 2024, to be followed by a phased global launch of the pigs, subject to receiving applicable regulatory approvals. Genus will be hosting a Capital Markets Event in London on 1 November 2023 to provide additional information on its PRRS resistant pig development, registration and commercialisation programme.お知らせ • Aug 24Genus plc Announces Lykele Van Der Broek to Step Down from the Genus BoardGenus plc announces that Lykele van der Broek, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the conclusion of the 2023 Annual General Meeting on 22 November 2023, after nine years' service as a Non-Executive Director. Russell Reynolds has been retained and is in the process of identifying potential successors for Lykele.お知らせ • Aug 11AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR. Ashurst LLP acted as legal advisor to N.M. Rothschild & Sons Limited in the transaction. AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd on August 9, 2023.お知らせ • Jun 07AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR.お知らせ • Dec 07+ 2 more updatesGenus plc to Report Fiscal Year 2023 Results on Sep 07, 2023Genus plc announced that they will report fiscal year 2023 results on Sep 07, 2023株主還元GENS.FUS BiotechsUS 市場7D-1.4%-1.6%-0.3%1Y14.6%34.3%24.0%株主還元を見る業界別リターン: GENS.F過去 1 年間で34.3 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: GENS.Fは、過去 1 年間で24 % のリターンを上げたUS市場を下回りました。価格変動Is GENS.F's price volatile compared to industry and market?GENS.F volatilityGENS.F Average Weekly Movementn/aBiotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: GENS.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のGENS.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19943,190JK Kokkewww.genusplc.comジーナス社は、北米、中南米、英国、その他のヨーロッパ、中東、ロシア、アフリカ、アジアで動物遺伝学会社として事業を展開している。同社は3つのセグメントで事業を展開している：ジーナスPIC、ジーナスABS、ジーナス研究開発。PICブランドで、豚肉生産用に様々な特徴を持つ豚を繁殖するための繁殖豚と精液を販売している。また、ABS、ジーナス、ボベックの各ブランドで、牛乳や肉牛生産用の様々な特徴を持つ子牛を繁殖させるための雄牛の精液や胚を販売している。さらに、酪農家に技術サービスも提供している。同社は1994年に法人化され、イギリスのベイジングストークを拠点としている。もっと見るGenus plc 基礎のまとめGenus の収益と売上を時価総額と比較するとどうか。GENS.F 基礎統計学時価総額US$2.14b収益（TTM）US$63.26m売上高(TTM)US$895.00m33.8xPER（株価収益率2.4xP/SレシオGENS.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GENS.F 損益計算書（TTM）収益UK£672.00m売上原価UK£402.40m売上総利益UK£269.60mその他の費用UK£222.10m収益UK£47.50m直近の収益報告Dec 31, 2025次回決算日Sep 10, 2026一株当たり利益（EPS）0.71グロス・マージン40.12%純利益率7.07%有利子負債／自己資本比率46.4%GENS.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.3%現在の配当利回り46%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/17 16:10終値2026/05/13 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genus plc 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Robert ChantryBerenbergMatthew LloydBNP ParibasAlexander JonesBofA Global Research15 その他のアナリストを表示
お知らせ • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.
お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026
お知らせ • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.
お知らせ • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.
お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdom
お知らせ • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.
お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026
お知らせ • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.
お知らせ • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.
お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdom
お知らせ • Sep 04Genus plc Proposes Final Dividend for the Year 2025, Payable on December 5, 2025Genus plc proposed a final dividend of 21.7 pence per share for 2025. This is subject to shareholders' approval at the AGM and we have therefore not included it as a liability in these Financial Statements. The total proposed and paid dividend for year ended 30 June 2025 is 32.0 pence per share (2024: 32.0 pence per share). It is proposed that the final dividend will be paid on 5 December 2025 to the shareholders on the register at the close of business on 7 November 2025.
お知らせ • May 02Genus plc Announces the Update in Relation to Its Innovative Prrs 1 Resistant Pig ProgrammeGenus announced that the U.S. Food and Drug Administration ("FDA") has approved the PRP gene edit for use in the U.S. food supply chain, in line with expectations. This landmark approval follows years of close collaboration with the FDA and is a significant step on the pathway to PRP commercialisation in the U.S. Genus believes successful U.S. commercialisation also requires approvals in key U.S. export markets, being Mexico, Canada and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China. Brazil, Colombia and, more recently, the Dominican Republic have already issued positive determinations for PRP, meaning those countries will regulate the PRP the same as any other pigs. PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. Recent research indicates that PRRS also increases the need for antibiotics by more than 200%.
お知らせ • Mar 13+ 1 more updateGenus plc Appoints Andy Russell as Chief Financial Officer, Effective August 1, 2025The Board of Genus plc announced that it has appointed Andy Russell as Chief Financial Officer. Andy will commence with Genus and join the Board on 1 August 2025, taking over from Alison Henriksen after she retires from the Company on 31 July 2025, after more than five years in the role. Andy is an experienced CFO, who will join Genus after nearly 12 years with global medical device manufacturer Smith & Nephew plc. He currently serves as Senior Vice President, Group Finance and M&A, operating as deputy to the Group CFO and leading approximately 400 people globally as he oversaw Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This follows a succession of increasingly senior roles within the organisation, including CFO for the Global Orthopedics division, Interim President for EMEA and CFO for EMEA (while also acting as Finance lead for Global M&A and Strategic Projects). Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last three of them as a Director, Transaction Services in the National Markets Division and the Private Equity Group.
お知らせ • Feb 26Genus plc Announces Retirement of Jason Chin as Non-Executive Director from the Board, Effective from the End of May 2025Genus plc announced that Professor Jason Chinhas informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board. The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded.
お知らせ • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025
お知らせ • Nov 21Genus plc Declares A Final DividendGenus plc declared a final dividend of 21.7 pence per Ordinary Share, at its AGM held on 20 November 2024.
お知らせ • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Oct 22Genus plc Announces Retirement of Alison Henriksen as Chief Financial Officer, Until 31 July 2025Genus announced that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.
お知らせ • Sep 05Genus plc Proposes Final Dividend for the Year Ended June 30, 2024, Payable on 6 December 2024Genus plc board proposed a final dividend of 21.7 pence per ordinary share, consistent with the prior year final dividend. Payable on, 6 December 2024 to the shareholders on the register at the close of business on 8 November 2024.
お知らせ • Feb 16Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024Genus plc provided earnings guidance for the first half of fiscal 2024. For the first half period, management expects to report revenue of £334 Million.
お知らせ • Dec 12Genus Appoints Ralph Heuser as Non-Executive Director, with effect from 1 January 2024Genus announced the appointment of Dr Ralph Heuser to the Board as a Non-Executive Director, with effect from 1 January 2024. Dr Heuser has had extensive experience in animal healthcare businesses globally, having worked at Pfizer, Boehringer Ingelheim, where he launched a PRRS vaccine in Germany, Novartis's Consumer and Animal Health divisions and more recentlyin global leadership roles at Elanco Animal Health, including as Vice President for Asia Pacific, Europe and International Commercial Operations. Dr Heuserhas a PhD in Agricultural Economics from the University of Bonn, Germany andis currently a Senior Advisor with Stonehaven Consulting (SC Group) AG. Dr Heuser brings widespread global experience in operations, commercial excellence, integration and the animal health industry generally, and his appointment follows an extensive search process using an external search agency.
お知らせ • Nov 24+ 2 more updatesGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024
お知らせ • Nov 23Genus plc Approves to Declare Final DividendGenus plc at its AGM held on 22 November 2023, approved to declare a final dividend of 21.7 pence per Ordinary Share.
お知らせ • Oct 08Colombian Government Gives Positive Determination for Genus's PRRS Virus-Resistant PigsGenus plc announced that the government of Colombia has given a favourable regulatory determination for Genus's Porcine Reproductive and Respiratory Syndrome virus ("PRRS") resistant pigs. This enables the future sale of such pigs in Colombia. PRRS is one of the most significant diseases in the pig industry, causing severe respiratory distress, increased secondary infections, pregnancy loss and increased morbidity and mortality. There are currently no effective vaccines or treatments. The creation of a PRRS resistant pig therefore represents a significant step forward in the welfare of pigs by protecting themthem from this devastating virus. It is estimated that PRRS costs the US and EU pig industry approximately $2 billion each year. Genus has used its gene editing platform to develop pigs resistant to PRRS, by deleting a very small portion of the pigs' DNA that encodes a protein that the virus uses to enter and infect the pigs' cells. With this small gene edit, the pig is resistant to PRRS, as the virus is unable to enter the cells and replicate. The Colombian government is the first to issue a determination for Genus's PRRS resistant pigs, enabling the future commercialisation of the pigs. The PRRS resistant pigs will be treated in the same way as any other pigs in Colombia. Further regulatory approvals for the PRRS resistant pig are also being sought in the United States, Canada, China, Japan, Mexico, Brazil and other countries. Genus anticipates a decision from the United States Food and Drug Administration in the first half of 2024, to be followed by a phased global launch of the pigs, subject to receiving applicable regulatory approvals. Genus will be hosting a Capital Markets Event in London on 1 November 2023 to provide additional information on its PRRS resistant pig development, registration and commercialisation programme.
お知らせ • Aug 24Genus plc Announces Lykele Van Der Broek to Step Down from the Genus BoardGenus plc announces that Lykele van der Broek, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the conclusion of the 2023 Annual General Meeting on 22 November 2023, after nine years' service as a Non-Executive Director. Russell Reynolds has been retained and is in the process of identifying potential successors for Lykele.
お知らせ • Aug 11AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR. Ashurst LLP acted as legal advisor to N.M. Rothschild & Sons Limited in the transaction. AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd on August 9, 2023.
お知らせ • Jun 07AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million.AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024. Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR.
お知らせ • Dec 07+ 2 more updatesGenus plc to Report Fiscal Year 2023 Results on Sep 07, 2023Genus plc announced that they will report fiscal year 2023 results on Sep 07, 2023
